| Description | The antibody COVOX-316 is a human mAb specific for SARS-CoV-2 Spike S1 protein. The IC50 value of the antibody against SARS-CoV-2 is 0.08 nM. The KD of the antibody for RBD is 0.13 nM. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Receptor-binding domain (RBD) |
| Affinity | 0.13 nM |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | The IC50 value of COVOX-316 is 0.08 nM. To determine the binding affinity of antibody to SARS-CoV-2 virus, virus was captured onto plates coated with mouse anti-SARSCoV-2 spike and then incubated with serial dilutions of SARS-CoV-2-specific human mAbs followed by ALP-conjugated anti-human IgG. The reaction was developed with PNPP substrate and stopped with NaOH. The absorbance was measured at 405 nm. Results are expressed as the percentage of total binding, with 100% binding determined from the Ab concentration that gave maximum absorbance. GraphPad PRISM software was used to perform nonlinear regression curve-fitting analyses of binding data to estimate dissociation constants (Kd). |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
